Who has used internal company documents for biomedical and public health research and where did they find them?

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Wieland, L Susan ^a   Rutkow, Lainie ^b   Vedula, S Swaroop ^c   Kaufmann, Christopher N ^b   Rosman, Lori M ^c   Twose, Claire ^c   Mahendraratnam, Nirosha ^b,d   Dickersin, Kay ^b  

^a BROWN UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Avalere Health LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; CITATION ANALYSIS; DOCUMENT EXAMINATION; DOCUMENTATION; DRUG INDUSTRY; FUNDING; INTERNAL COMPANY DOCUMENT; MEDICAL RESEARCH; PUBLIC HEALTH; SCIENTIFIC LITERATURE; TOBACCO INDUSTRY; DATA MINING; INDUSTRY; INFORMATION PROCESSING; MEDLINE; PROCEDURES; UTILIZATION;

BIOMEDICAL RESEARCH; DATA MINING; INDUSTRY; PUBLIC HEALTH; PUBMED; RECORDS AS TOPIC;

EID: 84900444377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094709     Document Type: Article

References (54)

1. Song F, Parekh S, Hooper L, Loke YK, Ryder J, et al. (2010) Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 14: iii, ix-xi, 1-193.
2. Turner EH, Knoepflmacher D, Shapley L (2012) Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med 9: e1001189.
3. Dickersin K, Chalmers I (2011) Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO. J R Soc Med 104: 532-538.
4. Vedula SS, Bero L, Scherer RW, Dickersin K (2009) Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 361: 1963-1971.
5. Dickersin K (1997) How important is publication bias? A synthesis of available data. AIDS Educ Prev 9: 15-21.
6. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L (2012) Industry sponsorship and research outcome. Cochrane Database Syst Rev 12: MR000033.
7. Dickersin K, Min YI, Meinert CL (1992) Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 267: 374-378.
8. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291: 2457-2465. (Pubitemid 38669189)
9. Decullier E, Lheritier V, Chapuis F (2005) Fate of biomedical research protocols and publication bias in France: retrospective cohort study. BMJ 331: 19.
10. Dickersin K, Min YI (1993) Publication bias: the problem that won't go away. Ann N Y Acad Sci 703: 135-146; discussion 146-138.
11. Chan AW, Krleza-Jeric K, Schmid I, Altman DG (2004) Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 171: 735-740. (Pubitemid 39319090)
12. Simes RJ (1986) Publication bias: the case for an international registry of clinical trials. J Clin Oncol 4: 1529-1541.
13. Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, et al. (2011) Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Database Syst Rev: MR000031.
14. Rising K, Bacchetti P, Bero L (2008) Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 5: e217; discussion e217.
15. Doshi P, Jefferson T, Del Mar C (2012) The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med 9: e1001201.
16. Krumholz HM, Ross JS, Gross CP, Emanuel EJ, Hodshon B, et al. (2013) A historic moment for open science: the Yale University Open Data Access Project and Medtronic. Ann Intern Med 158: 910-911.
17. Vedula SS, Li T, Dickersin K (2013) Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. PLoS Med 10: e1001378.
18. Vedula SS, Goldman PS, Rona IJ, Greene TM, Dickersin K (2012) Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation. Trials 13: 136.
19. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, et al. (2012) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 1: CD008965.
20. Hurt RD, Ebbert JO, Muggli ME, Lockhart NJ, Robertson CR (2009) Open doorway to truth: legacy of the Minnesota tobacco trial. Mayo Clin Proc 84: 446-456.
21. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T (2013) Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 346: f2865.
22. Doshi P, Jefferson T (2013) Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 3.
23. Hill KP, Ross JS, Egilman DS, Krumholz HM (2008) The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med 149: 251-258.
24. Freudenberg N (2012) The manufacture of lifestyle: the role of corporations in unhealthy living. J Public Health Policy 33: 244-256.
25. McDaniel PA, Malone RE (2009) The role of corporate credibility in legitimizing disease promotion. Am J Public Health 99: 452-461.
26. The UCSF Tobacco Documents Bibliography. Available: www.library.ucsf.edu/ tobacco/docsbiblio (Accessed 17 January 2013): UCSF Library and Center for Knowledge Management.
27. Drug Industry Document Archive. Available: http://dida.library.ucsf.edu/ (Accessed 11 February 2013): UCSF Library and Center for Knowledge Management.
28. Doshi P, Jones M, Jefferson T (2012) Rethinking credible evidence synthesis. BMJ 344: d7898.
29. The Cochrane Collaboration (2013) Cochrane Collaboration announces formal support for AllTrials initiative. News release 19 April 2013. Available: http://www.cochrane.org/node/4906 (Accessed 7 July 2013).
30. Food and Drug Administration (2013) Availability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for Comments. Federal Register. Available: https://www.federalregister.gov/articles/2013/06/ 04/2013-13083/availability-of-masked-and-de-identified-non-summary-safety-and- efficacy-data-request-for-comments (Accessed 7 July 2013).
31. Anderson SJ, McCandless PM, Klausner K, Taketa R, Yerger VB (2011) Tobacco documents research methodology. Tob Control 20 Suppl 2: ii8-11.
32. WHO (2004) The tobacco industry documents. What they are, what they tell us, and how to search them. Available: http://www.who.int/tobacco/ communications/TI-manual-content.pdf (Accessed 12 February, 2013).
33. Publication and access to clinical-trial data: an inclusive development process. Available: http://www.ema.europa.eu/ema/index.jsp?curl = pages/special-topics/general/general-content-000556.jsp. (Accessed December 15, 2013).
34. Chan AW (2012) Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ 344: d8013.
35. Psaty BM, Furberg CD, Ray WA, Weiss NS (2004) Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 292: 2622-2631. (Pubitemid 39577518)
36. Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145: 284-293. (Pubitemid 46768613)
37. Jureidini JN, McHenry LB, Mansfield PR (2008) Clinical trials and drug promotion: Selective reporting of study 329. International Journal of Risk and Safety in Medicine 20: 73-81. (Pubitemid 351526054)
38. McHenry LB, Jureidini JN (2008) Industry-sponsored ghostwriting in clinical trial reporting: a case study. Account Res 15: 152-167.
39. Psaty BM, Kronmal RA (2008) Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 299: 1813-1817. (Pubitemid 351549972)
40. Ross JS, Hill KP, Egilman DS, Krumholz HM (2008) Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 299: 1800-1812. (Pubitemid 351549971)
41. White J, Bandura A, Bero LA (2009) Moral disengagement in the corporate world. Account Res 16: 41-74.
42. Hetherington J, Dickersin K, Chalmers I, Meinert CL (1989) Retrospective and prospective identification of unpublished controlled trials: lessons from a survey of obstetricians and pediatricians. Pediatrics 84: 374-380. (Pubitemid 19193872)
43. Applbaum K (2009) Getting to yes: corporate power and the creation of a psychopharmaceutical blockbuster. Cult Med Psychiatry 33: 185-215.
44. Spielmans GI (2009) The promotion of olanzapine in primary care: an examination of internal industry documents. Soc Sci Med 69: 14-20.
45. Woods S, Tek C, Srihari VH (2011) Adverse drug effects not detected at licensing review: Regulatory autopsy of olanzapine. Schizophrenia Bulletin 37: 30.
46. Breggin PR (2006) Court filing makes public my previously suppressed analysis of Paxil's effects. Ethical Hum Psychol Psychiatry 8: 77-84.
47. Jureidini JN, McHenry LB (2011) Conflicted medical journals and the failure of trust. Account Res 18: 45-54.
48. Krumholz HM, Ross JS, Presler AH, Egilman DS (2007) What have we learnt from Vioxx? BMJ 334: 120-123. (Pubitemid 46173951)
49. Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM (2010) Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med 170: 2035-2036.
50. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA (2007) Characteristics and impact of drug detailing for gabapentin. PLoS Med 4: e134.
51. Landefeld CS, Steinman MA (2009) The Neurontin legacy-marketing through misinformation and manipulation. N Engl J Med 360: 103-106.
52. Fugh-Berman AJ (2010) The haunting of medical journals: how ghostwriting sold "HRT". PLoS Med 7: e1000335.
53. Bernschneider-Reif S, Oxler F, Freudenmann RW (2006) The origin of MDMA ("ecstasy")-separating the facts from the myth. Pharmazie 61: 966-972. (Pubitemid 44807273)
54. Greene JA (2005) Releasing the flood waters: diuril and the reshaping of hypertension. Bull Hist Med 79: 749-794.